Moleculin Biotech (MBRX)
(Delayed Data from NSDQ)
$2.55 USD
+0.01 (0.39%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $2.55 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth D Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MBRX 2.55 +0.01(0.39%)
Will MBRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MBRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MBRX
Lantheus (LNTH) to Report Q4 Earnings: What's in the Cards?
Moleculin (MBRX) Up 7% on Upbeat Updates From Annamycin Studies
MBRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Moleculin (MBRX) Posts Update From Lung Cancer Study, Stock Up
Here's Why Moleculin Biotech, Inc. (MBRX) Looks Ripe for Bottom Fishing
Moleculin Biotech, Inc. (MBRX) Upgraded to Buy: What Does It Mean for the Stock?
Other News for MBRX
Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
Moleculin Announces Closing of up to $16.5 Million Public Offering
Moleculin Biotech Raises Capital with Public Offering
Earnings week ahead: Zoom, Lowe's, Target, Baidu, XPeng, Zim Integrated and more
Moleculin Announces Pricing of up to $16.5 Million Public Offering